These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27832040)

  • 1. Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease.
    Deng XL; Ma R; Zhu HX; Zhu J
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):297-301. PubMed ID: 27832040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
    Wang X; Zhao B; Sun H; You H; Qu S
    Front Endocrinol (Lausanne); 2022; 13():866189. PubMed ID: 36072931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
    Ferrario MG; Lizán L; Montagnoli R; Ramírez de Arellano A
    Prim Care Diabetes; 2016 Jun; 10(3):220-6. PubMed ID: 26546244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the monotherapy of sitagliptin on glycemic control of patients with type 2 diabetes in different duration.
    Bai X; Li X; Li A; Wu L; Wang F; Geng J; Liu J; Bai X
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S821-S825. PubMed ID: 28734768
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
    Tomiyama H; Miwa T; Kan K; Matsuhisa M; Kamiya H; Nanasato M; Kitano T; Sano H; Ohno J; Iida M; Sata M; Yamada H; Maemura K; Tanaka A; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Nov; 15(1):150. PubMed ID: 27809848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
    Li B; Luo YR; Tian F; Chen YD; Tian JW; Ding Y; Zhu M; Li JW; Zhang YQ; Shi WM
    Atherosclerosis; 2020 May; 300():10-18. PubMed ID: 32247073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T; Higashi Y; Kihara Y; Yamada H; Sata M; Ueda S; Odawara M; Terauchi Y; Dai K; Ohno J; Iida M; Sano H; Tomiyama H; Inoue T; Tanaka A; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):134. PubMed ID: 27624168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
    Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
    J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
    J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
    Terauchi Y; Yamada Y; Ishida H; Ohsugi M; Kitaoka M; Satoh J; Yabe D; Shihara N; Seino Y
    Diabetes Obes Metab; 2017 Aug; 19(8):1188-1192. PubMed ID: 28294488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.
    Iwasaki T; Tomeno W; Yoneda M; Inamori M; Shirakawa J; Imajo K; Kawashima K; Terauchi Y; Nakajima A
    Hepatogastroenterology; 2012; 59(117):1522-5. PubMed ID: 22155853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.